基础胰岛素与胰高血糖素样肽-1受体激动剂联合治疗糖尿病的合理性被引量：7

导出

摘要英国糖尿病前瞻性研究（UKPDS）及其后续随访研究显示，通过早期强化治疗达到良好的血糖控制可明显减少2型糖尿病（T2DM）患者大血管和微血管并发症的风险。随着病程的延长，T2DM患者的胰岛B细胞功能进行性下降，单一降糖药物常不能长期维持血糖水平的稳定，常需联合应用两种或两种以上降糖药物，才能使空腹血糖、餐后血糖及糖化血红蛋白（HbAlc）达标。

作者田勃洪天配

机构地区北京大学第三医院内分泌科

出处《中华糖尿病杂志》 CAS 2012年第8期500-502,共3页 CHINESE JOURNAL OF DIABETES MELLITUS

基金国家自然科学基金资助项目（81000315,81070701）高等学校博士学科点专项科研基金资助项目（20100001110083）国家973计划资助项目（2012CB517502）

关键词英国糖尿病前瞻性研究胰高血糖素样肽-1受体激动剂基础胰岛素联合治疗胰岛B细胞功能理性微血管并发症早期强化治疗

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献15

1Holman RR,Paul SK,Bethel MA. 10-year follow-up of intensive glucose control in type 2 diabetes[J].New England Journal of Medicine,2008.1577-1589. 被引量：1
2Drucker D J,Nauck MA. The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J].The Lancet,2006.1696-1705. 被引量：1
3Drucker DJ. Glucagon-like peptides:regulators of cell proliferation,differentiation,and apoptosis[J].Molecular Endocrinology,2003.161-171. 被引量：1
4Drucker DJ. Develpoment of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes[J].Current Pharmaceutical Design,2001.1399-1412. 被引量：1
5Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review[J].Diabetes Technology and Therapeutics,2010.11-24. 被引量：1
6Russell-Jones D,Vaag A,Schmitz O. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met +SU):a randomised controlled trial[J].Diabetologia,2009.2046-2055. 被引量：1
7Bunck MC,Diamant M,Cornér A. One-year treatment with exenatide improves beta-cell function,compared with insulin glargine,in metformin-treated type 2 diabetic patients:a randomized,controlled trial[J].Diabetes Care,2009.762-768. 被引量：1
8Barnett AH,Burger J,Johns D. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2diabetes previously uncontrolled with metformin or a sulfonylurea:a multinational,randomized,open-label,two-period,crossover noninferiority trial[J].Clinical Therapeutics,2007.2333-2348. 被引量：1
9Heine RJ,Van Gaal LF,Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes:a randomized trial[J].Annals of Internal Medicine,2005.559-569. 被引量：1
10Sheffield CA,Kane MP,Busch RS. Safety and efficacy of exenatide in combination with insulin in patients with type 2diabetes mellitus[J].Endocrine Practice,2008.285-292. 被引量：1